alpha Linolenic acid / TumCI Cancer Research Results

aLinA, alpha Linolenic acid: Click to Expand ⟱
Features:

alpha Linolenic acid — Alpha-linolenic acid is an essential plant-derived omega-3 polyunsaturated fatty acid (PUFA; 18:3n-3) found in flax/chia, walnuts, and certain vegetable oils. It is a dietary lipid nutrient (not a regulated anticancer drug) and a metabolic precursor that can be elongated/desaturated to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), albeit inefficiently in most adults. Standard abbreviation: ALA (clarify vs “alpha-lipoic acid,” which is also abbreviated ALA in some contexts).

Primary mechanisms (ranked):

  1. Membrane phospholipid incorporation and lipid microdomain remodeling (raft-dependent signaling context-dependent)
  2. Eicosanoid and specialized pro-resolving mediator tone shift via ω-6/ω-3 substrate competition and partial conversion to EPA/DHA
  3. Inflammatory signaling modulation (e.g., NF-κB/cytokine tone; context- and tissue-dependent)
  4. PPAR signaling and lipid-metabolic reprogramming (context-dependent; often stronger for EPA/DHA than for ALA itself)
  5. Redox biology effects dominated by PUFA peroxidation susceptibility (secondary; can be protective or injurious depending on antioxidant context)

Bioavailability / PK relevance: Absorbed as a dietary fat (enhanced with meals) and incorporated into circulating lipids and cell membranes; systemic biology is dominated by tissue incorporation plus limited bioconversion. Adult conversion of ALA to EPA is typically in the single-digit to low-teens percent range, while DHA conversion is usually <1% (variable by sex, baseline diet, and competing linoleic acid intake).

In-vitro vs systemic exposure relevance: Many mechanistic “direct anticancer” effects reported in cell culture use supraphysiologic free-fatty-acid conditions (often albumin-poor) that can exaggerate lipotoxicity and lipid-peroxidation stress; in vivo effects are more plausibly mediated by membrane remodeling and lipid-mediator shifts rather than acute cytotoxicity.

Clinical evidence status: Human evidence is strongest for cardiometabolic endpoints and mortality associations; oncology-specific evidence for ALA as an anticancer intervention is limited and heterogeneous (mostly observational). Meta-analyses report mixed signals for cancer risk (including historical concern for prostate cancer in some datasets), and omega-3 supplementation trials overall have not shown clear reductions in cancer incidence; ALA-specific RCT evidence for cancer outcomes remains sparse.

Alpha Linolenic acid naturally-occurring fatty acid. Found in vegetable oils, plant oils, nuts and meat.
• Alpha linolenic acid (ALA) is an essential omega-3 fatty acid commonly found in plant sources such as flaxseed, chia seeds, walnuts, and certain vegetable oils.
• As an essential fatty acid, ALA must be obtained from the diet and serves as a precursor to longer-chain omega-3 fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
• While ALA itself is not a strong antioxidant, its downstream metabolites can indirectly support antioxidant defense systems.
• By reducing oxidative stress, ALA may help protect cellular DNA from damage that can trigger carcinogenesis.

Alpha-linolenic acid (ALA) mechanistic axes relevant to cancer biology

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Membrane lipid remodeling and lipid microdomains Growth signaling platforms ↔ (context-dependent); receptor clustering may shift Membrane fluidity ↑ R, G Signal microenvironment modulation Central “direct” mechanism for ALA is incorporation into phospholipids; downstream signaling changes are model- and composition-dependent and may be stronger after partial conversion to EPA.
2 Eicosanoid balance and lipid mediator tone Pro-inflammatory eicosanoids ↓ (context-dependent) Inflammation resolution tone ↑ (context-dependent) G Lipid mediator rebalancing ALA competes with ω-6 substrates and can modestly raise EPA; DHA rise is usually minimal, limiting DHA-linked effects.
3 NF-κB and cytokine signaling NF-κB ↓ or ↔ (model-dependent) Inflammatory tone ↓ (context-dependent) R, G Anti-inflammatory modulation Often secondary to lipid-mediator shifts and membrane effects; direction can vary by cell type and stimulus.
4 PPAR axis and lipid metabolism programs PPAR signaling ↔ or ↑ (context-dependent); lipid metabolism rewiring Metabolic flexibility ↑ G Transcriptional metabolic modulation PPAR effects are well-established for fatty-acid ligands broadly; relative potency may be higher for long-chain ω-3s than for ALA.
5 AMPK and energy-stress signaling AMPK ↑ (context-dependent) Energy homeostasis support ↔ R, G Metabolic checkpoint engagement Reported in some systems, but less consistent than for EPA/DHA; may couple to downstream mTOR tone in select models.
6 PI3K AKT mTOR Survival signaling ↓ (model-dependent) ↔ R, G Growth pathway modulation Usually secondary to membrane composition and inflammatory tone; not a universal primary mechanism.
7 ROS and lipid peroxidation susceptibility ROS ↑ (high concentration only) or ↔; lipid peroxidation ↑ (context-dependent) Oxidative injury ↔ or ↑ (context-dependent) P, R, G Redox stress or redox buffering PUFAs are oxidation-prone; outcomes depend strongly on antioxidant capacity, iron availability, and culture vs in vivo context.
8 Apoptosis and mitochondrial integrity Apoptosis ↑ (model-dependent) ↔ G Cell fate shift Often downstream of membrane/redox changes; direct cytotoxicity is more likely under non-physiologic in-vitro conditions.
9 Angiogenesis and VEGF axis VEGF ↓ (model-dependent) ↔ G Pro-angiogenic signaling dampening Frequently secondary to inflammatory signaling shifts rather than a direct ALA-specific target.
10 HIF-1α and hypoxia programs HIF-1α ↓ (model-dependent) ↔ G Stress-adaptation modulation May track with changes in inflammatory/redox tone; evidence is preclinical and context-sensitive.
11 Chemosensitization Therapy response ↑ (context-dependent) — G Adjunct response modulation Signals exist for ω-3s broadly, but ALA-specific and clinically reproducible effects are uncertain.
12 Clinical Translation Constraint EPA/DHA conversion limited; competing linoleic acid can reduce conversion Diet- and phenotype-dependent exposure — PK and biology constraint Many endpoints attributed to ω-3 biology are driven more robustly by EPA/DHA; ALA’s impact depends on dose, background diet, and individual metabolism.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (lipid incorporation begins; oxidative interactions)
  • R: 30 min–3 hr (early signaling + inflammatory shifts)
  • G: >3 hr (membrane remodeling, phenotype-level effects)

Alpha-linolenic acid (ALA) axes relevant to Alzheimer’s disease biology

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Brain lipid supply and membrane composition ↔ to ↑ (context-dependent) Supports neuronal/glial membrane lipid remodeling ALA is a precursor pool; central effects depend on dietary intake, transport, and limited conversion to EPA/DHA. DHA accretion from ALA is typically minimal in adults.
2 Neuroinflammation and microglial activation tone ↓ or ↔ (context-dependent) Dampens pro-inflammatory signaling in some models Often mediated indirectly via ω-6/ω-3 substrate competition and downstream lipid mediator balance; genotype (e.g., APOE) and baseline diet may modify effects.
3 Blood–brain barrier integrity and neurovascular unit ↑ (context-dependent) Barrier support, vascular inflammation reduction Preclinical and mechanistic literature suggests lipid composition influences BBB properties; clinical specificity for ALA remains uncertain.
4 Aβ production/clearance balance ↔ (model-dependent) Potential shift in amyloidogenic processing or clearance pathways Evidence is heterogeneous; effects reported for ω-3 biology are more consistently linked to DHA/EPA than to ALA per se.
5 Tau phosphorylation and proteostasis stress responses ↔ (model-dependent) Possible modulation of kinase/phosphatase balance and stress signaling Not a well-established primary ALA target; if present, likely secondary to inflammatory/metabolic tone shifts.
6 Brain energy metabolism and insulin signaling ↔ to ↑ (context-dependent) Supports metabolic resilience (glucose handling) in some contexts Human biomarker studies often focus on EPA/DHA; ALA associations may reflect broader dietary patterns and fatty-acid network effects.
7 ROS and lipid peroxidation ↔ (context-dependent); lipid peroxidation risk ↑ (oxidative, low-antioxidant contexts) Shifts ROS production vs oxidation susceptibility ALA can reduce inflammation-linked ROS generation in some settings, but as an unsaturated PUFA it increases oxidizable substrate; net “ROS injury” depends on redox/iron/antioxidant context and whether ALA is membrane-incorporated vs free fatty acid.
8 Synaptic plasticity and neurotransmission support ↔ to ↑ (context-dependent) Potential support for synaptic function via membrane effects More robust evidence exists for DHA in synaptic membranes; ALA may contribute indirectly or in deficiency/low ω-3 states.
9 Clinical Translation Constraint — Exposure and effect-size limitation ALA-specific cognitive/AD trial evidence is limited; conversion to DHA is typically very low, and background linoleic acid intake can reduce long-chain ω-3 formation.


TumCI, Tumor Cell invasion: Click to Expand ⟱
Source:
Type:
Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms:

1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion.

2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue.

3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment.

4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream.

5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body.

6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection.

7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs.

8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis.
Scientific Papers found: Click to Expand⟱
1123- aLinA,    Linoleic acid induces an EMT-like process in mammary epithelial cells MCF10A
- in-vitro, BC, NA - in-vitro, NA, MCF10
TumCP↑, E-cadherin↓, Snail↑, Twist↑, ZEB2↑, FAK↑, NF-kB↑, MMP2↓, MMP9↓, *EMT↑, TumCI↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Migration ⓘ

E-cadherin↓, 1,   FAK↑, 1,   MMP2↓, 1,   MMP9↓, 1,   Snail↑, 1,   TumCI↑, 1,   TumCP↑, 1,   Twist↑, 1,   ZEB2↑, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↑, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Proliferation, Differentiation & Cell State ⓘ

EMT↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: TumCI, Tumor Cell invasion
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:116  Target#:324  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page